Sareum Holdings plc (AIM: SAR)

London flag London · Delayed Price · Currency is GBP · Price in GBX
22.73
+0.23 (1.00%)
Jan 17, 2025, 10:42 AM GMT+1
-56.71%
Market Cap 28.69M
Revenue (ttm) n/a
Net Income (ttm) -3.42M
Shares Out 124.75M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,591
Average Volume 168,709
Open 22.75
Previous Close 22.50
Day's Range 22.13 - 23.00
52-Week Range 10.00 - 54.13
Beta -0.93
RSI 38.26
Earnings Date Dec 27, 2024

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which h... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 5
Stock Exchange London Stock Exchange AIM
Ticker Symbol SAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.